ARTICLE | Clinical News
Cenicriviroc: Phase I started
September 26, 2016 7:00 AM UTC
Tobira began an open-label, U.S. Phase I trial to evaluate 5 mg oral evogliptin with or without 150 mg oral cenicriviroc in 12 healthy volunteers. Tobira has exclusive, worldwide rights to cenicriviroc from Takeda (see BioCentury, Aug. 6, 2007). In April, Tobira granted Dong-A exclusive, South Korean rights to cenicriviroc as a single agent or in combination with evogliptin while Dong-A granted Tobira exclusive rights to evogliptin as a single agent or in combination with cenicriviroc in the U.S., Canada, Europe and Australia (see BioCentury, April 26). Evogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. ...